Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL (“Coris”) to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 Million
Avacta (AIM: AVCT) Equity fundraise of £3.25 million
Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, is pleased to announce that it has raised gross proceeds of £3.25 million from long term, high net worth
Avacta Group PLC (AIM: AVCT) Q2 2025 Business Update
Outlining Progress Against Strategic Objectives
Avacta Group PLC (AIM:AVCT) Management Team Appointments
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
Avacta Group PLC (AIM:AVCT) New Response in Phase 1b Trial
New Response in the FAP-Dox (AVA6000) Phase 1b Trial
Avacta Group PLC (AIM:AVCT) Preliminary Full Year 2024 Results
Preliminary Results for the Year Ended December 31, 2024
Avacta Group PLC (AIM:AVCT) Avacta Change in Prelim Date Part 2
Update on timing of preliminary results announcement
Avacta Group PLC (AIM:AVCT) Board appointments
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the appointments of David Bryant and
Avacta Group PLC (AIM:AVCT) Update on timing of preliminary results
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces that the preliminary results for
Avacta Group PLC (AIM:AVCT) Notice of Results
Investor Presentation via Investor Meet Company
Avacta Group PLC (AIM:AVCT) Investor Webinar on 15 May 2025 at 6.00 pm (BST).
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that Dr Christina
Avacta Group Plc (AIM:AVCT) A Company Developing Next-Generation Cancer Therapies
Avacta Group plc (AVCT) is a life sciences company developing next-generation cancer therapies that deliver powerful anti-tumour payloads directly to the tumour site.